Inventor · disambiguated record
Douglas A. Treco
Also filed as: TRECO DOUGLAS · TRECO DOUGLAS A
61 granted patents·22 pending applications·2,474 citations·filing 1994–2024
99Inventor score
Files withTRANSKARYOTIC THERAPIES INC31RA PHARMACEUTICALS INC23SHIRE HUMAN GENETIC THERAPIES10SELDEN RICHARD F4TRANSKARYOTIC THERAPIES INC A4
Top patents by PatentIndex Score
83 records- 0198US6670178B1In Vivo production and delivery of insulinotropin for gene therapyTRANSKARYOTIC THERAPIES INC·Filed 2000·Granted Dec 30, 2003·105 cites·11 claims
- 0298US5733761AProtein production and protein deliveryTRANSKARYOTIC THERAPIES INC·Filed 1995·Granted Mar 31, 1998·317 cites·70 claims
- 0397US10435438B2Modulation of complement activityRA PHARMACEUTICALS INC·Filed 2019·Granted Oct 8, 2019·12 cites·21 claims
- 0497US10106579B2Modulation of complement activityRA PHARMACEUTICALS INC·Filed 2015·Granted Oct 23, 2018·19 cites·20 claims
- 0597US6048729AIn vivo protein production and delivery system for gene therapyTRANSKARYOTIC THERAPIES INC·Filed 1994·Granted Apr 11, 2000·74 cites·28 claims
- 0697US5641670AProtein production and protein deliveryTRANSKARYOTIC THERAPIES INC·Filed 1994·Granted Jun 24, 1997·502 cites·30 claims
- 0796US10208089B2Modulation of complement activityRA PHARMACEUTICALS INC·Filed 2018·Granted Feb 19, 2019·12 cites·21 claims
- 0896US6083725ATranfected human cells expressing human α-galactosidase A proteinTRANSKARYOTIC THERAPIES INC·Filed 1997·Granted Jul 4, 2000·180 cites·37 claims
- 0995US10328115B2Modulators of complement activityRA PHARMACEUTICALS INC·Filed 2018·Granted Jun 25, 2019·15 cites·22 claims
- 1095US6395884B1Therapy for α-galactosidase a deficiencyTRANSKARYOTIC THERAPIES INC·Filed 2000·Granted May 28, 2002·59 cites·17 claims
- 1194US11014965B2Modulation of complement activityRA PHARMACEUTICALS INC·Filed 2020·Granted May 25, 2021·3 cites·18 claims
- 1294US10588936B2Modulators of complement activityRA PHARMACEUTICALS INC·Filed 2019·Granted Mar 17, 2020·13 cites·20 claims
- 1394US9937222B2Modulators of complement activityRA PHARMACEUTICALS INC·Filed 2016·Granted Apr 10, 2018·14 cites·15 claims
- 1493US6566099B1Nucleic acid encoding a chimeric polypeptideTRANSKARYOTIC THERAPIES INC·Filed 2000·Granted May 20, 2003·36 cites·8 claims
- 1592US7833742B2Treatment of α-galactosidase A deficiencySHIRE HUMAN GENETIC THERAPIES·Filed 2006·Granted Nov 16, 2010·21 cites·26 claims
- 1692US6924365B1Optimized messenger RNATRANSKARYOTIC THERAPIES INC·Filed 1999·Granted Aug 2, 2005·136 cites·30 claims
- 1792US6063630ATargeted introduction of DNA into primary or secondary cells and their use for gene therapyTRANSKARYOTIC THERAPIES INC·Filed 1994·Granted May 16, 2000·93 cites·24 claims
- 1892US5968502AProtein production and protein deliveryTRANSKARYOTIC THERAPIES INC·Filed 1995·Granted Oct 19, 1999·91 cites·84 claims
- 1991US11752190B2Modulators of complement activityRA PHARMACEUTICALS INC·Filed 2020·Granted Sep 12, 2023·2 cites·18 claims
- 2091US10918691B2Modulators of complement activityRA PHARMACEUTICALS INC·Filed 2020·Granted Feb 16, 2021·2 cites·21 claims
- 2191US6458574B1Treatment of a α-galactosidase a deficiencyTRANSKARYOTIC THERAPIES INC·Filed 1999·Granted Oct 1, 2002·82 cites·26 claims
- 2290US6537542B1Targeted introduction of DNA into primary or secondary cells and their use for gene therapy and protein productionTRANSKARYOTIC THERAPIES INC·Filed 2000·Granted Mar 25, 2003·20 cites·11 claims
- 2390US5580734AMethod of producing a physical map contigous DNA sequencesTRANSKARYOTIC THERAPIES INC·Filed 1994·Granted Dec 3, 1996·161 cites·4 claims
- 2489US11123399B2Modulators of complement activityRA PHARMACEUTICALS INC·Filed 2017·Granted Sep 21, 2021·4 cites·15 claims
- 2589US5994127AIn vivo production and delivery of erythropoietin or insulinotropin for gene therapyTRANSKARYOTIC THERAPIES INC·Filed 1994·Granted Nov 30, 1999·78 cites·25 claims
- 2688US10835574B2Modulators of complement activityRA PHARMACEUTICALS INC·Filed 2016·Granted Nov 17, 2020·7 cites·33 claims
- 2787US12239684B2Modulators of complement activityRA PHARMACEUTICALS INC·Filed 2023·Granted Mar 4, 2025·0 cites·13 claims
- 2886US6048524AIn vivo production and delivery of erythropoietin for gene therapyTRANSKARYOTIC THERAPIES INC·Filed 1995·Granted Apr 11, 2000·42 cites·9 claims
- 2985US6048724AMethod of producing clonal cell strains which express exogenous DNA encoding glucagon-like peptide 1TRANSKARYOTIC THERAPIES INC·Filed 1995·Granted Apr 11, 2000·42 cites·3 claims
- 3084US9238676B2Peptide and peptidomimetic inhibitorsRA PHARMACEUTICALS INC·Filed 2013·Granted Jan 19, 2016·2 cites·20 claims
- 3184US6270989B1Protein production and deliveryTRANSKARYOTIC THERAPIES INC·Filed 1995·Granted Aug 7, 2001·64 cites·356 claims
- 3283US9523113B2Treatment of α-galactosidase A deficiencySHIRE HUMAN GENETIC THERAPIES·Filed 2016·Granted Dec 20, 2016·3 cites·17 claims
- 3382US11535650B1Modulation of complement activityRA PHARMACEUTICALS INC·Filed 2022·Granted Dec 27, 2022·0 cites·2 claims
- 3482US10272132B2Peptide and peptidomimetic inhibitorsRA PHARMACEUTICALS INC·Filed 2018·Granted Apr 30, 2019·1 cites·20 claims
- 3582US6692737B1In vivo protein production and delivery system for gene therapyTRANSKARYOTIC THERAPIES INC·Filed 2000·Granted Feb 17, 2004·8 cites·14 claims
- 3682US6187305B1Targeted introduction of DNA into primary or secondary cells and their use for gene therapy and protein productionTRANSKARYOTIC THERAPIES INC·Filed 1995·Granted Feb 13, 2001·43 cites·8 claims
- 3781US6303379B1Vivo protein production and delivery system for gene therapyTRANSKARYOTIC THERAPIES INC·Filed 1999·Granted Oct 16, 2001·38 cites·63 claims
- 3879US7122354B2Nucleic acid encoding a chimeric polypeptideTRANSKARYOTIC THERAPIES INC·Filed 2002·Granted Oct 17, 2006·5 cites·7 claims
- 3978US11965040B2Modulation of complement activityRA PHARMACEUTICALS INC·Filed 2021·Granted Apr 23, 2024·0 cites·12 claims
- 4078US6054288AIn vivo protein production and delivery system for gene therapyTRANSKARYOTIC THERAPIES INC·Filed 1995·Granted Apr 25, 2000·43 cites·18 claims
- 4175US11707503B2Modulators of complement activityRA PHARMACEUTICALS INC·Filed 2021·Granted Jul 25, 2023·0 cites·20 claims
- 4275US9644004B2Peptide and peptidomimetic inhibitorsRA PHARMACEUTICALS INC·Filed 2015·Granted May 9, 2017·1 cites·20 claims
- 4375US2025090624A1Modulators of complement activityRA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4474US10954287B2Ras binding peptides and methods of useRA PHARMACEUTICALS INC·Filed 2017·Granted Mar 23, 2021·1 cites·22 claims
- 4574US7410799B2In vivo production and delivery of erythropoietin or insulinotropin for gene therapySHIRE HUMAN GENETIC THERAPIES·Filed 2004·Granted Aug 12, 2008·1 cites·13 claims
- 4673US9267166B2Treatment of α-galactosidase A deficiencyTRECO DOUGLAS A·Filed 2010·Granted Feb 23, 2016·2 cites·23 claims
- 4772US11116823B2Treatment of α-galactosidase a deficiencyTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Sep 14, 2021·0 cites·25 claims
- 4871US11723949B2Modulators of complement activityRA PHARMACEUTICALS INC·Filed 2021·Granted Aug 15, 2023·0 cites·16 claims
- 4971US6242218B1Genomic sequences for protein production and deliveryTRANSKARYOTIC THERAPIES INC·Filed 1999·Granted Jun 5, 2001·23 cites·30 claims
- 5071US2010062526A1Optimized messenger rnaSELDEN RICHARD F·Filed 2009·Application pending·0 cites
Showing the top 50 of 83 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Douglas A. Treco files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →